Warnex Medical Laboratories

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex announced that it has sold its medical laboratories division to Gamma-Dynacare Medical Laboratories for C$7.5 million (US$7.3 million).

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex today said that it has signed an agreement to serve as exclusive distributor of 10 of DeCode Genetics' tests in Canada.

New Releases


Septin9 Colorectal Cancer Test

The company's Medical Laboratories testing and services division has received a renewal of its COLA accreditation.

So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.

Warnex will market the tests and send tissue samples from its customers to Rosetta's Philadelphia-based lab for analysis.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.